Cloudbreak Pharma Profit Highlights Turnaround in Ophthalmic Biotech
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. (HKG: 2592) announced a positive profit alert for the...
Cloudbreak Pharma
Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...
Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development
Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...
Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia
Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese...
Cloudbreak Pharma Files for Hong Kong IPO with Focus on Ophthalmic Innovations
Cloudbreak Pharma Inc., a Cayman Islands-registered pharmaceutical company, has filed for an initial public offering...